FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285992899> ?p ?o ?g. }

• W4285992899 endingPage "559" @default.
• W4285992899 startingPage "547" @default.
• W4285992899 abstract "The efficacy and safety of tralokinumab, a fully human monoclonal antibody that specifically neutralizes interleukin-13, plus topical corticosteroids (TCS) as needed were evaluated over 32 weeks in the phase III ECZTRA 3 trial. Significantly more tralokinumab- versus placebo-treated patients achieved the primary endpoints of Investigator’s Global Assessment (IGA) score of 0/1 and 75% improvement in Eczema Area and Severity Index (EASI-75) and all confirmatory endpoints at Week 16. This post hoc analysis investigated the impact of tralokinumab plus TCS on atopic dermatitis (AD) severity, symptoms, and health-related quality of life (QoL) over the entire 32-week treatment period of ECZTRA 3, including all patients initiated on tralokinumab irrespective of the response achieved at Week 16. Patients were randomized 2:1 to receive subcutaneous tralokinumab 300 mg or placebo every 2 weeks (q2w) with TCS as needed for an initial 16 weeks. At Week 16, patients who achieved the clinical response criteria (IGA 0/1 and/or EASI-75) with tralokinumab were re-randomized 1:1 to tralokinumab q2w or every 4 weeks (q4w), with TCS as needed, for another 16 weeks. Patients not achieving the clinical response criteria with tralokinumab received tralokinumab q2w plus TCS from Week 16. All patients randomized to tralokinumab in the initial treatment period were pooled for this analysis, irrespective of response at Week 16 or dosing regimen beyond Week 16. Continued tralokinumab (q2w, N = 164; q4w, N = 69) plus TCS treatment provided progressive improvements from Week 16 onwards in AD signs, with 70.2% (177/252) of patients achieving EASI-75 and 50.4% (127/252) achieving EASI-90 at Week 32. Improvements in patient-reported outcomes were observed within the first few weeks of tralokinumab q2w plus TCS treatment and were sustained throughout the 32-week period. At Week 32, patients initiated on tralokinumab q2w plus TCS achieved a relative improvement versus baseline of 70.8% (standard error (SE), 2.4) in eczema-related sleep interference numeric rating scale (NRS) and 66.8% (SE, 3.1) in Dermatology Life Quality Index (DLQI). Mean TCS use during Weeks 16–32 ranged from 9.2 to 13.6 g (SE, 1.2–2.0) q2w. Most patients (89.9% (222/247)) initiated on tralokinumab q2w plus TCS achieved a meaningful improvement in at least one of the three disease domains, including AD signs (EASI-50), symptoms (pruritus NRS improvement ≥ 3), and QoL (DLQI improvement ≥ 4) at Week 16. Of patients initiated on tralokinumab q2w plus TCS, 53.4% (132/247) achieved a clinically meaningful improvement in all three domains at Week 16 (vs. placebo, 28.5% (35/123); p < 0.001). Continued tralokinumab treatment plus TCS as needed provides progressive and sustained improvements in AD signs, symptoms, and health-related QoL over 32 weeks. NCT03363854; study start date: 22 February 2018; primary completion date: 8 March 2019; study completion date: 26 September 2019. Atopic dermatitis (AD) is a chronic inflammatory disease that causes excessively dry and itchy skin that can negatively impact sleep and overall quality of life for patients. Topical corticosteroids (TCS) are the most common medication used for AD, but they are not able to control the most severe cases. Tralokinumab is a treatment injected under the skin that targets an immune messenger protein called interleukin 13, which plays a key role in driving the signs and symptoms of AD. The ECZTRA 3 clinical trial, funded by LEO Pharma, compared the use of TCS as needed with either tralokinumab or placebo in over 350 adult patients with moderate-to-severe AD over a 32-week period. After 16 weeks, more patients taking tralokinumab plus TCS had clear or almost clear skin compared with patients taking placebo plus TCS. Patients taking tralokinumab also used less TCS than patients taking placebo. In new analyses presented here, we found that the proportion of patients with clear or almost clear skin continued to increase with on-going treatment from Week 16 to Week 32. Tralokinumab plus TCS treatment also led to clinically meaningful improvements in outcomes important to patients, including itch, sleep, and quality of life. Improvements occurred early, within the first few weeks of therapy, and lasted through Week 32. Our assessment of multiple outcomes over time clearly demonstrates the positive impact of tralokinumab on different aspects of AD." @default.
• W4285992899 created "2022-07-21" @default.
• W4285992899 creator A5006332291 @default.
• W4285992899 creator A5012738162 @default.
• W4285992899 creator A5017062027 @default.
• W4285992899 creator A5018416880 @default.
• W4285992899 creator A5019267451 @default.
• W4285992899 creator A5032789219 @default.
• W4285992899 creator A5040410444 @default.
• W4285992899 creator A5042438814 @default.
• W4285992899 creator A5058073606 @default.
• W4285992899 creator A5065645102 @default.
• W4285992899 creator A5088865400 @default.
• W4285992899 creator A5089195756 @default.
• W4285992899 date "2022-07-01" @default.
• W4285992899 modified "2023-10-17" @default.
• W4285992899 title "Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis" @default.
• W4285992899 cites W2058562555 @default.
• W4285992899 cites W2287402718 @default.
• W4285992899 cites W2559769990 @default.
• W4285992899 cites W2591120832 @default.
• W4285992899 cites W2610814011 @default.
• W4285992899 cites W2760088364 @default.
• W4285992899 cites W2908925106 @default.
• W4285992899 cites W2914603675 @default.
• W4285992899 cites W2952535698 @default.
• W4285992899 cites W2970372587 @default.
• W4285992899 cites W3033412594 @default.
• W4285992899 cites W3047057201 @default.
• W4285992899 cites W3090227268 @default.
• W4285992899 cites W3091046625 @default.
• W4285992899 cites W3125034399 @default.
• W4285992899 cites W3136297743 @default.
• W4285992899 cites W3189956257 @default.
• W4285992899 cites W3193360717 @default.
• W4285992899 cites W3195786665 @default.
• W4285992899 doi "https://doi.org/10.1007/s40257-022-00702-2" @default.
• W4285992899 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35857179" @default.
• W4285992899 hasPublicationYear "2022" @default.
• W4285992899 type Work @default.
• W4285992899 citedByCount "10" @default.
• W4285992899 countsByYear W42859928992023 @default.
• W4285992899 crossrefType "journal-article" @default.
• W4285992899 hasAuthorship W4285992899A5006332291 @default.
• W4285992899 hasAuthorship W4285992899A5012738162 @default.
• W4285992899 hasAuthorship W4285992899A5017062027 @default.
• W4285992899 hasAuthorship W4285992899A5018416880 @default.
• W4285992899 hasAuthorship W4285992899A5019267451 @default.
• W4285992899 hasAuthorship W4285992899A5032789219 @default.
• W4285992899 hasAuthorship W4285992899A5040410444 @default.
• W4285992899 hasAuthorship W4285992899A5042438814 @default.
• W4285992899 hasAuthorship W4285992899A5058073606 @default.
• W4285992899 hasAuthorship W4285992899A5065645102 @default.
• W4285992899 hasAuthorship W4285992899A5088865400 @default.
• W4285992899 hasAuthorship W4285992899A5089195756 @default.
• W4285992899 hasBestOaLocation W42859928991 @default.
• W4285992899 hasConcept C126322002 @default.
• W4285992899 hasConcept C142724271 @default.
• W4285992899 hasConcept C16005928 @default.
• W4285992899 hasConcept C168563851 @default.
• W4285992899 hasConcept C187212893 @default.
• W4285992899 hasConcept C203092338 @default.
• W4285992899 hasConcept C204787440 @default.
• W4285992899 hasConcept C27081682 @default.
• W4285992899 hasConcept C2778329239 @default.
• W4285992899 hasConcept C2780699399 @default.
• W4285992899 hasConcept C2781413609 @default.
• W4285992899 hasConcept C535046627 @default.
• W4285992899 hasConcept C67761136 @default.
• W4285992899 hasConcept C71924100 @default.
• W4285992899 hasConceptScore W4285992899C126322002 @default.
• W4285992899 hasConceptScore W4285992899C142724271 @default.
• W4285992899 hasConceptScore W4285992899C16005928 @default.
• W4285992899 hasConceptScore W4285992899C168563851 @default.
• W4285992899 hasConceptScore W4285992899C187212893 @default.
• W4285992899 hasConceptScore W4285992899C203092338 @default.
• W4285992899 hasConceptScore W4285992899C204787440 @default.
• W4285992899 hasConceptScore W4285992899C27081682 @default.
• W4285992899 hasConceptScore W4285992899C2778329239 @default.
• W4285992899 hasConceptScore W4285992899C2780699399 @default.
• W4285992899 hasConceptScore W4285992899C2781413609 @default.
• W4285992899 hasConceptScore W4285992899C535046627 @default.
• W4285992899 hasConceptScore W4285992899C67761136 @default.
• W4285992899 hasConceptScore W4285992899C71924100 @default.
• W4285992899 hasFunder F4320332071 @default.
• W4285992899 hasIssue "4" @default.
• W4285992899 hasLocation W42859928991 @default.
• W4285992899 hasLocation W42859928992 @default.
• W4285992899 hasLocation W42859928993 @default.
• W4285992899 hasLocation W42859928994 @default.
• W4285992899 hasLocation W42859928995 @default.
• W4285992899 hasOpenAccess W4285992899 @default.
• W4285992899 hasPrimaryLocation W42859928991 @default.
• W4285992899 hasRelatedWork W1977360779 @default.
• W4285992899 hasRelatedWork W1991975354 @default.
• W4285992899 hasRelatedWork W2273800213 @default.
• W4285992899 hasRelatedWork W2341111541 @default.
• W4285992899 hasRelatedWork W2766528424 @default.

• next